Abivax Reports Positive Phase 3 PRO Data For Obefazimod In Ulcerative Colitis Showing Consistent Quality-Of-Life Improvements

Abivax SA (Euronext Paris, Nasdaq: ABVX), a clinical-stage biotechnology company developing therapies that regulate the immune response in chronic inflammatory diseases, announced new patient-reported outcomes (PRO) from its Phase 3 ABTECT 8-week induction trials of obefazimod in adults with moderate-to-severe ulcerative colitis (UC). The PRO data complement the trials’ previously reported clinical efficacy results and provide insights into how patients perceive improvements in symptoms, daily functioning, and quality of life.

The evaluation of PROs included several key measures such as bowel urgency, nocturnal bowel movement frequency, fatigue scores, and quality of life indices like FACIT-F, IBDQ, EQ-5D-5L, and workplace productivity. The results demonstrated consistent improvements across all instruments, reinforcing obefazimod’s meaningful impact on patients’ daily experiences. Experts emphasized that addressing symptoms like bowel urgency and fatigue plays a critical role in helping UC patients regain normalcy and emotional well-being.

Abivax CEO Marc de Garidel highlighted that these findings strengthen obefazimod’s profile as a potential long-term treatment for UC. The company plans to present detailed analyses of the PRO data at an upcoming medical conference and anticipates sharing results from its 44-week maintenance trial in the second quarter of 2026. Together, the Phase 3 efficacy and PRO results underscore obefazimod’s promise in improving both clinical and quality-of-life outcomes for patients with ulcerative colitis.